Evidence map›Paper›PMID 32518358›Full record

ReviewNature reviews. Cardiology2020

Pregnancy and cardiovascular disease.

Karishma P Ramlakhan, Mark R Johnson, Jolien W Roos-Hesselink

Abstract readReview
PubMed Publisher
In one paragraph

Review in Nature reviews. Cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 146 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
146citing papers in PubMed, 6 pooled it
20.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

146 citing papers in PubMed, 6 syntheses or guidelines pooled it, 261 citations in OpenAlex.

  1. Maternal, Valvular and Foetal Outcomes of Pregnancy Following Aortic Valve Replacement.European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. 2025 European Society of Cardiology guidelines for the management of cardiovascular disease and pregnancy : Statement of endorsement by the NVVC.Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation · 2026
    Review
  12. Article
  13. Observational
  14. Article
  15. [Perioperative outcomes and anesthetic management of pregnancy termination in patients with pulmonary hypertension].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

86 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Karishma P RamlakhanDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands.ORCID http://orcid.org/0000-0002-6741-2603
Mark R JohnsonAcademic Department of Obstetrics and Gynaecology, Imperial College London, Chelsea and Westminster Hospital, London, UK.
Jolien W Roos-HesselinkDepartment of Cardiology, Erasmus University Medical Center, Rotterdam, Netherlands. j.roos@erasmusmc.nl.ORCID http://orcid.org/0000-0002-6770-3830
Erasmus MC · NLChelsea and Westminster Hospital · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cardiovascular disease complicates 1-4% of pregnancies - with a higher prevalence when including hypertensive disorders - and is the leading cause of maternal death. In women with known cardiovascular pathology, such as congenital heart disease, timely counselling is possible and the outcome is fairly good. By contrast, maternal mortality is high in women with acquired heart disease that presents during pregnancy (such as acute coronary syndrome or aortic dissection). Worryingly, the prevalence of acquired cardiovascular disease during pregnancy is rising as older maternal age, obesity, diabetes mellitus and hypertension become more common in the pregnant population. Management of cardiovascular disease in pregnancy is challenging owing to the unique maternal physiology, characterized by profound changes to multiple organ systems. The presence of the fetus compounds the situation because both the cardiometabolic disease and its management might adversely affect the fetus. Equally, avoiding essential treatment because of potential fetal harm risks a poor outcome for both mother and child. In this Review, we examine how the physiological adaptations during pregnancy can provoke cardiometabolic complications or exacerbate existing cardiometabolic disease and, conversely, how cardiometabolic disease can compromise the adaptations to pregnancy and their intended purpose: the development and growth of the fetus.

Indexed as

Cardiovascular Physiological PhenomenaAcute Coronary SyndromeAntihypertensive AgentsAortic DissectionArrhythmias, CardiacAspirinCardiac OutputCardiomyopathiesDiabetes, GestationalDisease ProgressionEndocarditisFemaleHumansHypertensionHypertension, Pregnancy-InducedHypoglycemic AgentsAntihypertensive AgentsAspirinHypoglycemic AgentsPlatelet Aggregation Inhibitors

Identifiers

PMID32518358
OpenAlexW3033333104

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.